natalizumab treatment for multiple sclerosis: updates and considerations for safer treatment in jcv positive patients
Clicks: 123
ID: 229006
2014
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.0
/100
123 views
11 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #275 of 475 articles by views in communications in computer and information science
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 475 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Natalizumab is currently one of the best options for treatment of patients with Multiple Sclerosis who have failed traditional prior therapies. However, prolonged use, prior immunosuppressive therapy and anti-JCV antibody status have been associated with increased risk of developing progressive multifocal leukoencephalopathy (PML). The evaluation of these conditions has been used to estimate risks of PML in these patients, and distinct (sometimes extreme) approaches are used to avoid the PML onset. At this time, the biggest issue facing the use of Natalizumab is how to get a balance between the risks and the benefits of the treatment. Hence, strategies for monitor JCV-positive patients undergoing Natalizumab treatment are deeply necessary. To illustrate it, we monitored JCV/DNA in blood and urine of a patient receiving Natalizumab for 12 months. We also bring to discussion the effectiveness of the current methods used for risk evaluation, and the real implications of viral reactivation.
| Reference Key |
nali2014arquivosnatalizumab
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Luiz Henrique da Silva Nali;Lenira Moraes;Maria Cristina Domingues Fink;Dagoberto Callegaro;Camila Malta Romano;Augusto Cesar Penalva de Oliveira |
| Journal | communications in computer and information science |
| Year | 2014 |
| DOI |
10.1590/0004-282X20140142
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.